Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK FOSAMAX SALES REACH $58 MIL. IN U.S. DURING THIRD QUARTER; COZAAR, CRIXIVAN NEAR $50 MIL.; PFIZER ZITHROMAX SALES MORE THAN DOUBLE TO $75 MIL. IN U.S.

Executive Summary

Merck's Fosamax is tracking for over $200 mil. in sales in the U.S. during its first full year on the market. Fosamax sales reached $58 mil. in the U.S. for the third quarter, Merck reported Oct. 16. The osteoporosis agent was launched in the U.S. in October 1995, and has generated $141 mil. in sales so far in 1996. Worldwide sales are $79 mil. for the quarter and $189 mil. for the year to date, the company said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel